HCW Biologics Statistics
Total Valuation
HCW Biologics has a market cap or net worth of $2.53 million. The enterprise value is $7.60 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HCW Biologics has 6.73 million shares outstanding. The number of shares has increased by 116.30% in one year.
| Current Share Class | 6.73M |
| Shares Outstanding | 6.73M |
| Shares Change (YoY) | +116.30% |
| Shares Change (QoQ) | +49.73% |
| Owned by Insiders (%) | 9.41% |
| Owned by Institutions (%) | 2.18% |
| Float | 6.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 50.54 |
| Forward PS | n/a |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.99 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 140.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.11, with a Debt / Equity ratio of 2.46.
| Current Ratio | 0.11 |
| Quick Ratio | 0.09 |
| Debt / Equity | 2.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -16.17 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -31.19% |
| Return on Invested Capital (ROIC) | -103.53% |
| Return on Capital Employed (ROCE) | -395.18% |
| Weighted Average Cost of Capital (WACC) | 9.64% |
| Revenue Per Employee | $1,506 |
| Profits Per Employee | -$619,408 |
| Employee Count | 36 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -95.17% in the last 52 weeks. The beta is 0.90, so HCW Biologics's price volatility has been similar to the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -95.17% |
| 50-Day Moving Average | 0.54 |
| 200-Day Moving Average | 2.51 |
| Relative Strength Index (RSI) | 42.55 |
| Average Volume (20 Days) | 539,341 |
Short Selling Information
The latest short interest is 110,641, so 1.64% of the outstanding shares have been sold short.
| Short Interest | 110,641 |
| Short Previous Month | 42,868 |
| Short % of Shares Out | 1.64% |
| Short % of Float | 1.81% |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HCW Biologics had revenue of $54,232 and -$22.30 million in losses. Loss per share was -$10.63.
| Revenue | 54,232 |
| Gross Profit | 10,846 |
| Operating Income | -13.66M |
| Pretax Income | -7.96M |
| Net Income | -22.30M |
| EBITDA | -12.62M |
| EBIT | -13.66M |
| Loss Per Share | -$10.63 |
Full Income StatementBalance Sheet
The company has $1.95 million in cash and $6.81 million in debt, with a net cash position of -$4.86 million or -$0.72 per share.
| Cash & Cash Equivalents | 1.95M |
| Total Debt | 6.81M |
| Net Cash | -4.86M |
| Net Cash Per Share | -$0.72 |
| Equity (Book Value) | 2.76M |
| Book Value Per Share | 0.84 |
| Working Capital | -18.78M |
Full Balance SheetCash Flow
| Operating Cash Flow | -13.39M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 1.04M |
| Net Borrowing | 22,377 |
| Free Cash Flow | -13.39M |
| FCF Per Share | -$1.99 |
Full Cash Flow StatementMargins
| Gross Margin | 20.00% |
| Operating Margin | -25,192.71% |
| Pretax Margin | -14,677.14% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HCW Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -116.30% |
| Shareholder Yield | -116.30% |
| Earnings Yield | -813.59% |
| FCF Yield | -488.61% |
Analyst Forecast
The average price target for HCW Biologics is $35.00, which is 9,208.51% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.00 |
| Price Target Difference | 9,208.51% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 552.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 11, 2025. It was a reverse split with a ratio of 1:40.
| Last Split Date | Apr 11, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:40 |
Scores
HCW Biologics has an Altman Z-Score of -8.67 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.67 |
| Piotroski F-Score | 1 |
